Custom service
Peptide-RNA Conjugation
Couple peptides to rna strands while preserving rna integrity end to end
Teams come to this service when they need to couple peptides to RNA strands while preserving RNA integrity end to end. We typically start from 5'-maleimide RNA synthesis and ligation, add RNase-inactivating handling workflow where the application demands it, and close the loop with denaturing HPLC purification so the final RNase-free conjugate with integrity electropherogram behaves consistently across lots.
Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 4–7 weeks timeline holds in practice.
RNA aptamer–peptide constructs
Cap and modification chemistry research
GMP mRNA–peptide drug substance
Conjugates whose payload cannot tolerate aqueous coupling conditions
Every conjugation batch is documented from vial to vial: carrier lot, payload lot, reagent lots, reaction conditions and purification chromatograms. The release package contains the loading ratio measured by an orthogonal method (UV, ICP-MS or amino-acid analysis), identity by mass spectrometry where the conjugate permits it, and residual-free-payload data.
Service Highlights
- 5'-maleimide RNA synthesis and ligation as the default route, with RNase-inactivating handling workflow held as a proven fallback
- Denaturing HPLC purification worked into the design where the application requires it
- Carrier and payload compatibility screened in a small feasibility batch before full material is committed
- Analytical confirmation of every intermediate before the final release
- Unreacted payload driven below the detection limit of the release assay before purification is closed
- RNase-free conjugate with integrity electropherogram delivered with a complete conjugation or synthesis certificate
How the work runs
Scope & design
We review the payload, the carrier and the intended assay or study, and propose between 5'-maleimide RNA synthesis and ligation and RNase-inactivating handling workflow as candidate routes.
Feasibility screen
A milligram-scale screen compares loading, residual payload and activity across the candidate conditions.
Production conjugation
The selected condition is executed at project scale with in-process sampling at fixed time points.
Purification
Size-exclusion, dialysis or magnetic separation removes free payload and by-products.
Characterization & release
Identity, loading ratio and functional activity are measured against the agreed specification.
Documentation & hand-off
RNase-free conjugate with integrity electropherogram is packaged with the full batch record, released for shipment after QC sign-off.
Specifications & timeline
- Turnaround
- 4–7 weeks
- Typical scale
- 0.1–50 mg conjugate per batch
- Chemistry options
- 5'-maleimide RNA synthesis and ligation; RNase-inactivating handling workflow; denaturing HPLC purification
- Deliverable
- RNase-free conjugate with integrity electropherogram
- QC package
- HPLC/SEC trace, MALDI-TOF or ESI-MS, UV/Vis or ICP-MS loading ratio
- Shipping
- Blue ice or dry ice as the payload requires, with a cold-chain manifest
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.